Tuesday, November 07, 2023 5:09:52 PM
Hog wash HG,
Per your comment, "There are 7 publications that detail the deficiencies in the trial and the bias that makes any conclusions from the trial suspect."
The 7 publications are based on low level, paid bashers compared to the 100's of publications supporting NWBO, DCVax-L, but you already knew this
information since you are the expert in the Bio field???
Per your comment, "Only when the trial was virtually completed and the PFS primary endpoint had FAILED, did they attempt to post hoc "dredesgin"??? the trial to add an R/R/ GBM arm using the placebo arm."
Once again, the PFS primary endpoint was a statistically guess and in the end the OS results proved outstanding as the OS in the golden standard, but again,
you already knew this was the case.
Per your last comment, "Don't FDA is going to buy it.", you can remove the Don't to make a clear and true statement, IMPO.
Per your comment, "There are 7 publications that detail the deficiencies in the trial and the bias that makes any conclusions from the trial suspect."
The 7 publications are based on low level, paid bashers compared to the 100's of publications supporting NWBO, DCVax-L, but you already knew this
information since you are the expert in the Bio field???
Per your comment, "Only when the trial was virtually completed and the PFS primary endpoint had FAILED, did they attempt to post hoc "dredesgin"??? the trial to add an R/R/ GBM arm using the placebo arm."
Once again, the PFS primary endpoint was a statistically guess and in the end the OS results proved outstanding as the OS in the golden standard, but again,
you already knew this was the case.
Per your last comment, "Don't FDA is going to buy it.", you can remove the Don't to make a clear and true statement, IMPO.
Bullish
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
